Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
MT GENEX, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 25%, Oct-Dec Ordinary Profit Increases by 93%
9820 MT GENEX CORPORATION 【J-GAAP】
Earnings ReportMT GENEX CORPORATION <9820> [TSE Std] announced its financial results after the market closed on February 6th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) increased 25.2% from the same period last year, reaching 343 million yen. However, Progress toward the full-year plan of 597 million yen was 57.5%, also falling below the five-year average of 71.4%.
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to March period (4Q) is expected to expand 61.8% from the same period last year, reaching 254 million yen.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit increased 92.8% from the same period last year, reaching 160 million yen. The operating profit margin significantly improved from 8.8% in the same period last year to 13.4%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Dec, 2023 | 2,952 | 390 | 402 | 253 | 235.4 | 88.9 | Feb 9, 2024 | J-GAAP |
| Apr - Dec, 2024 | 2,775 | 258 | 274 | 165 | 153.7 | 63.6 | Feb 7, 2025 | J-GAAP |
| Apr - Dec, 2025 | 3,281 | 325 | 343 | 209 | 194.9 | 57.5 | Feb 6, 2026 | J-GAAP |
| YoY | +18.2% | +26.0% | +25.2% | +26.7% | +26.8% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 2,073 | 231 | 240 | 151 | 140.8 | 40 | May 12, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 2,898 | 415 | 414 | 270 | 250.9 | 40 | Nov 6, 2025 | J-GAAP |
| YoY | +39.8% | +79.7% | +72.5% | +78.8% | +78.2% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 3,790 | 438 | 452 | 277 | 257.9 | 40 | May 13, 2024 | J-GAAP |
| Mar, 2025 | 3,950 | 410 | 431 | 264 | 246.2 | 40 | May 12, 2025 | J-GAAP |
| Mar, 2026 Guidance | 5,000 | 582 | 597 | 377 | 350.3 | 40 | May 12, 2025 | J-GAAP |
| YoY | +26.6% | +42.0% | +38.5% | +42.8% | +42.3% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 898 | 79 | 83 | 52 | 48.4 | 8.8 | Feb 7, 2025 | J-GAAP |
| Jan - Mar, 2025 | 1,175 | 152 | 157 | 99 | 92.3 | 12.9 | May 12, 2025 | J-GAAP |
| Apr - Jun, 2025 | 976 | 66 | 75 | 41 | 38.2 | 6.8 | Aug 8, 2025 | J-GAAP |
| Jul - Sep, 2025 | 1,126 | 101 | 108 | 66 | 61.6 | 9.0 | Nov 7, 2025 | J-GAAP |
| Oct - Dec, 2025 | 1,179 | 158 | 160 | 102 | 95.1 | 13.4 | Feb 6, 2026 | J-GAAP |
| YoY | +31.3% | +100.0% | +92.8% | +96.2% | +96.4% |
Related Articles
NICHICON, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 13%
TAKAMISAWA, First Half Ordinary Profit Decreases by 28%, Oct-Dec Ordinary Profit Decreases by 17%
SAPPORO CLINICAL LAB, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 5%, Oct-Dec Ordinary Profit Decreases by 9%
SEKI, Apr-Dec (Cumulative 3Q) Ordinary Profit Turns to Loss, Oct-Dec Ordinary Profit Decreases by 42%
CL Holdings, Net Income Forecast for Last Fiscal Year Revised Upward by 12%, Dividend Revised Upward by 2 Yen
Paraca, Oct-Dec (1Q) Ordinary Profit Decreases by 1%
CMK, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 20%
KAKEN PHARMA, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 96%, Oct-Dec Ordinary Profit Decreases by 91%
TAIYO YUDEN, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 47%
HARIMA B.STEM, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 17%